Please assess the completion status of the following clinical trial:

Trial Title: Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. .endoscopy and biopsy verified rectal cancer within 12cm from anal verge;~2. .primary MRI, TRUS, abdomino-chest CT diagnosed early or intermediate or bad Stage II/III rectal cancer;~3. .age from 20-75;~4. .with informed consent;~Exclusion Criteria:~1. .refuse the further treatment after recruiting;~2. .diagnosis of peritoneal metastasis in the surgery;

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- chemotherapy group (Type: EXPERIMENTAL): patients receive 4 cycles of Xelox

Based on this trial design, predict the completion outcome and termination type (if applicable).